Authors
Muhammad Sameer Hashmi, Muhammad Aqif Ilyas
Published in
PloS one. Volume 21. Issue 11. Pages e0361802. Epub Nov 03, 2026.
Abstract
Early detection of hepatocellular carcinoma (HCC) remains challenging in hepatitis-endemic settings such as Pakistan, where surveillance commonly relies on ultrasonography and alpha-fetoprotein (AFP), both of which have limited sensitivity for early-stage disease. This study evaluated the diagnostic performance of serum Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II), complete blood count (CBC) parameters, and CBC-derived hematological indices for discriminating HCC from non-malignant chronic liver disease (CLD).
We conducted a case-control biomarker study involving 160 adults with CLD at Liaquat University Hospital, Sindh, Pakistan, between October 2025 and March 2026, including 74 patients with established HCC and 86 with non-malignant CLD. Serum PIVKA-II was measured using electrochemiluminescence immunoassay. CBC-derived neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, systemic immune-inflammation index, and red cell distribution width-to-platelet ratio were calculated. Between-group differences were assessed using non-parametric methods, and receiver operating characteristic (ROC) analysis evaluated discriminatory performance. Benjamini-Hochberg correction was applied to prespecified families of multiple comparisons.
PIVKA-II demonstrated the strongest discriminatory performance, with an area under the ROC curve (AUC) of 0.753 (95% CI, 0.670-0.827). At a cutoff of >82.1 mAU/mL, sensitivity was 86.4% and specificity was 56.0%. Platelet count (AUC, 0.642) and the RDW-to-platelet ratio (AUC, 0.638) also demonstrated significant between-group differences that remained significant after false discovery rate correction, although their discriminatory performance was modest. PIVKA-II discrimination was substantially higher among patients with vascular invasion (AUC, 0.853) and advanced BCLC stage C/D disease (AUC, 0.853) than among those with early/intermediate BCLC A/B disease (AUC, 0.571). A combined model incorporating PIVKA-II, lymphocyte percentage, and platelet count yielded an AUC of 0.784, but did not significantly improve discrimination compared with PIVKA-II alone (p = 0.166). Bootstrap validation showed minimal optimism in the overall AUC; however, the optimal PIVKA-II cutoff demonstrated substantial variability, with a 95% percentile range of 58.7-715.8 mAU/mL. This was corroborated by an independent 10-fold cross-validation analysis, which yielded a comparable mean AUC of 0.751 for PIVKA-II (optimism = +0.002).
PIVKA-II demonstrated fair diagnostic discrimination between HCC and non-malignant CLD, with relatively high sensitivity but limited specificity. Its substantially lower performance in early/intermediate-stage disease and the marked instability of the optimal cutoff indicate that PIVKA-II should be considered a complementary biomarker rather than a standalone diagnostic test. Larger multicenter studies with standardized control populations and independent external validation are needed to establish robust population-specific thresholds and determine the incremental clinical value of combining PIVKA-II with hematological parameters.
PMID:
42976211
Bibliographic data and abstract were imported from PubMed on 04 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 15
- Comments 0